Compugen Ltd (CGEN)
Last updated: 2026-10-21 18:23:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Compugen Ltd (CGEN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.15, with a market capitalization of $186.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.43 to $3.24. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$186.61M | |
$2.15 | |
$19.90 | |
$0.34 | |
$2.14 | |
119.91K | |
252.41K | |
-- | |
$3.24 | |
$1.43 | |
-- | |
-- |
Compugen Ltd (CGEN) Stock Price Today
Compugen Ltd (CGEN) is currently trading at $2.15 as of 2026-10-21 18:21:00, up 0.23% ($0.00) from the previous close of $2.14
During today's regular trading session, CGEN has traded between $0.34 and $19.90, with a trading volume of 119.91K shares. The current price is near the lower end of today's range.
Compugen Ltd (CGEN) 7-Day Stock Price Change
Over the past seven days, Compugen Ltd (CGEN) moved from $2.07 to $2.15, representing a gain of 3.62% ($0.08).
The stock traded between $1.93 and $2.20 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 306.34 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
CGEN 52-Week Price Position
Position in Range: 39.6%
CGEN is currently trading at $2.15, placing it 39.6% of the way from its 52-week low of $1.43 to its 52-week high of $3.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Compugen Ltd (CGEN)?
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Compugen Ltd Information
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Compugen Ltd (CGEN) Stock on MEXC
Eligible investors can buy real shares of Compugen Ltd (CGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Compugen Ltd (CGEN) stock price today?
2.Is CGEN stock going up or down today?
3.What is CGEN pre-market price?
4.What is CGEN after-hours price?
5.Is CGEN stock trading now?
6.Where does CGEN sit relative to its 52-week high and low?
7.What sector is Compugen Ltd in?
8.What is Compugen Ltd's market capitalization and where is it listed?
9.How is CGEN valued in terms of P/E ratio and EPS?
10.Does Compugen Ltd pay a dividend?
Explore More US Stocks
Search Stocks
CGEN Stock Calculator
Estimate the value between CGEN shares and USD.
CGEN Shares to USD
1.00 CGEN shares = 2.145 USD
Calculations are estimates based on the latest available price and are for reference only.


